Achieve Life Sciences ACHV Proceeds From Exercise Of Overallotment Option Net Of Issuance Costs
Proceeds From Exercise Of Overallotment Option Net Of Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Achieve Life Sciences in its filing.
Tagged under the XBRL concept achv:ProceedsFromExerciseOfOverallotmentOptionNetOfIssuanceCosts.
The official record: Achieve Life Sciences’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Achieve Life Sciences's proceeds from exercise of overallotment option net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Achieve Life Sciences's proceeds from exercise of overallotment option net of issuance costs?
- Achieve Life Sciences (ACHV) reported proceeds from exercise of overallotment option net of issuance costs of $1M in Q4 2025.
- What does proceeds from exercise of overallotment option net of issuance costs mean?
- Cash inflows generated from the exercise of an overallotment option, often referred to as a greenshoe option, net of associated issuance costs. This indicates the company's ability to raise additional capital during equity offerings based on market demand.